GKOS (Glaukos) Float Percentage Of Total Shares Outstanding: 82.51% (As of Jun. 26, 2026)


GKOS Glaukos Corp GKOS
80 GF Score
Price $144.42
GF Value $135.47
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Glaukos Float Percentage Of Total Shares Outstanding?

Glaukos GKOS +1.30% 80 Float Percentage Of Total Shares Outstanding is 82.51% as of Jun. 26, 2026. GuruFocus rates GKOS with a GF Score™ of 80/100 and a GF Value™ of $135.47 (Fairly Valued). The stock has 6 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Glaukos's float shares is 48.46 Mil. Glaukos's total shares outstanding is 58.73 Mil. Glaukos's float percentage of total shares outstanding is 82.51%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Glaukos's Insider Ownership is 1.26%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Glaukos's Institutional Ownership is 109.39%.

GKOS
80GF Score
Glaukos Corp GKOS
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glaukos Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Glaukos's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=48.46/58.73
=82.51%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 82.51% mean?
Glaukos (GKOS) has a Float Percentage Of Total Shares Outstanding of 82.51% as of Jun. 26, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Glaukos and its competitors.
Is Glaukos' Float Percentage Of Total Shares Outstanding too high?
Glaukos' current Float Percentage Of Total Shares Outstanding is 82.51%. Overall, Glaukos has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Float Percentage Of Total Shares Outstanding compare to LIVN and BIO?
Glaukos' Float Percentage Of Total Shares Outstanding of 82.51% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Medical Devices & Instruments company?
A good Float Percentage Of Total Shares Outstanding depends on the Medical Devices & Instruments industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Glaukos and its competitors. Glaukos's current Float Percentage Of Total Shares Outstanding is 82.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Fairly Valued. The stock's GF Value™ is $135.47, compared to a current price of $144.42 — trading 6.6% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 82.51%. Glaukos' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Glaukos (GKOS), the current Float Percentage Of Total Shares Outstanding is 82.51% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (GKOS) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of $144.42 is trading 6.6% above its estimated GF Value™ of $135.47. GuruFocus considers Glaukos to be Fairly Valued.

Key valuation signals for GKOS:

  • Float Percentage Of Total Shares Outstanding: 82.51%
  • GF Value™: $135.47 vs. price of $144.42 (6.6% above fair value)
  • GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glaukos Business Description

Other Exchanges 6GJ:Germany
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
80GF Score

Get the complete analysis for GKOS

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$144.42
Price
$135.47
GF Value